Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash from Investing Activities (2020 - 2025)

Xeris Biopharma Holdings' Cash from Investing Activities history spans 6 years, with the latest figure at -$333000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 103.32% year-over-year to -$333000.0, compared with a TTM value of -$696000.0 through Dec 2025, down 114.25%, and an annual FY2025 reading of -$696000.0, down 114.25% over the prior year.
  • Cash from Investing Activities for Q4 2025 was -$333000.0 at Xeris Biopharma Holdings, down from -$71000.0 in the prior quarter.
  • The five-year high for Cash from Investing Activities was $36.6 million in Q4 2021, with the low at -$44.0 million in Q1 2023.
  • Average Cash from Investing Activities over 5 years is $6.5 million, with a median of $8.8 million recorded in 2022.
  • Year-over-year, Cash from Investing Activities soared 404.92% in 2021 and then plummeted 754.84% in 2023.
  • Tracing XERS's Cash from Investing Activities over 5 years: stood at $36.6 million in 2021, then tumbled by 74.95% to $9.2 million in 2022, then surged by 62.17% to $14.9 million in 2023, then crashed by 32.63% to $10.0 million in 2024, then crashed by 103.32% to -$333000.0 in 2025.
  • Per Business Quant, the three most recent readings for XERS's Cash from Investing Activities are -$333000.0 (Q4 2025), -$71000.0 (Q3 2025), and -$279000.0 (Q2 2025).